Site icon pharmaceutical daily

Celsius Therapeutics Names Scientific Advisers

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Celsius Therapeutics, a biotechnology company pioneering new precision medicines for patients with cancer and autoimmune disease by harnessing the power of single-cell RNA sequencing and human biology at scale, today announced the appointments of six scientific advisers.

“As Celsius prepares to advance our first programs into the clinic, we are entering a transitional point in our evolution,” said Tariq Kassum, M.D., President and CEO of Celsius. “We are thrilled to welcome this esteemed group of academic leaders – world-renowned experts in inflammatory bowel disease, oncology, immunobiology, single-cell genomics, machine learning and computational biology – to help advance our mission to bring novel precision medicines to patients with cancer and autoimmune disease.”

Celsius’ scientific advisers include:

About Celsius Therapeutics

Celsius Therapeutics is a biotechnology company developing novel precision medicines in autoimmune disease and cancer by harnessing the power of single cell RNA sequencing and human biology at scale. The company’s first therapeutic candidate is an anti-TREM1 antibody for the treatment of inflammatory bowel disease, and the company has multiple ongoing drug discovery programs in oncology. Celsius is based in Cambridge, Mass. For more information, please visit www.celsiustx.com, or follow us on LinkedIn or Twitter.

Contacts

Katie Engleman, 1AB

katie@1abmedia.com

Exit mobile version